"Sentara Heart Hospital is recognized as a destination medical center nationally recognized for offering quality comprehensive heart care from advance diagnostics and imaging to minimally invasive heart procedures, heart surgery and heart transplants. On the campus of Sentara Norfolk General Hospital, the hospital consistently ranks among the nation's top heart programs in U.S. News & World Report . In the 2016-17 rankings, the cardiology and heart surgery program ranked 24th in the country, which marks the program's 17th year among the nation's elite top 50 hospitals in the survey."

During the past decade, Sentara Cardiovascular Research Institute conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 16 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 9 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sentara Cardiovascular Research Institute" #1 sponsor was "United Therapeutics" with 8 trials, followed by "Edwards Lifesciences" with 4 trials sponsored, "Actelion" with 3 trials sponsored, "Abbott Medical Devices" with 2 trials sponsored and "CardioFocus" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sentara Cardiovascular Research Institute" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "CAS Medical Systems, Inc." with 1 trials as a collaborator, "Columbia University" with 1 trials as a collaborator, "Northwestern University" with 1 trials as a collaborator and "ResMed Foundation" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Sentara Cardiovascular Research Institute" are "Pulmonary Arterial Hypertension" (9 trials), "Heart Failure" (4 trials), "Pulmonary Hypertension" (4 trials), "Aortic Stenosis" (3 trials) and "Atrial Fibrillation" (3 trials). Many other conditions were trialed in "Sentara Cardiovascular Research Institute" in a lesser frequency.

Most popular intervention types in "Sentara Cardiovascular Research Institute" are "Drug" (20 trials), "Device" (16 trials), "Other" (4 trials), "Procedure" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Oral treprostinil" (2 trials), "Ralinepag" (2 trials), "AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation" (1 trials) and "CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sentara Cardiovascular Research Institute" are 38 trials for "All" genders.

Currently, there are NaN active trials in "Sentara Cardiovascular Research Institute". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 20 completed trials in Sentara Cardiovascular Research Institute, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Sentara Cardiovascular Research Institute, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 10 trials that are defined as “Not Applicable".